FTC Complaint Against Sanofi/Maze Acquisition Results in Deal Termination

The FTC announced on Monday its intention to block Sanofi’s proposed acquisition of an exclusive license to Maze Therapeutics’ therapy in development for treatment of Pompe disease and hours later Sanofi announced that it was cancelling the deal.

On Monday, the FTC issued an administrative complaint and authorized a lawsuit in federal court alleging the deal, valued at up to $755 million, would eliminate a nascent competitor poised to challenge Sanofi’s monopoly in the Pompe disease therapy market.

Sanofi’s response to the FTC announcement was brief, “Sanofi is disappointed with the Federal Trade Commission’s announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics ... The delay associated with a long litigation has led Sanofi to conclude that it would not be in the best interests of patients to contest this litigation and Sanofi will therefore be terminating the agreement with Maze in accordance with its terms.”

Read the FTC Complaint here.

To read the whole story, click here to subscribe.

Related Topics